233 related articles for article (PubMed ID: 35183534)
1. The contributory roles of the CXCL12/CXCR4/CXCR7 axis in normal and malignant hematopoiesis: A possible therapeutic target in hematologic malignancies.
Mehrpouri M
Eur J Pharmacol; 2022 Apr; 920():174831. PubMed ID: 35183534
[TBL] [Abstract][Full Text] [Related]
2. CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies.
Khare T; Bissonnette M; Khare S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298991
[TBL] [Abstract][Full Text] [Related]
3. Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions.
Huynh C; Dingemanse J; Meyer Zu Schwabedissen HE; Sidharta PN
Pharmacol Res; 2020 Nov; 161():105092. PubMed ID: 32758634
[TBL] [Abstract][Full Text] [Related]
4. Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer.
Nazari A; Khorramdelazad H; Hassanshahi G
Int J Clin Oncol; 2017 Dec; 22(6):991-1000. PubMed ID: 29022185
[TBL] [Abstract][Full Text] [Related]
5. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies.
Daniel SK; Seo YD; Pillarisetty VG
Semin Cancer Biol; 2020 Oct; 65():176-188. PubMed ID: 31874281
[TBL] [Abstract][Full Text] [Related]
6. The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow.
Shakir M; Tang D; Zeh HJ; Tang SW; Anderson CJ; Bahary N; Lotze MT
Pancreas; 2015 May; 44(4):528-34. PubMed ID: 25872129
[TBL] [Abstract][Full Text] [Related]
7. The role of the CXCL12-CXCR4/CXCR7 axis in the progression and metastasis of bone sarcomas (Review).
Liao YX; Zhou CH; Zeng H; Zuo DQ; Wang ZY; Yin F; Hua YQ; Cai ZD
Int J Mol Med; 2013 Dec; 32(6):1239-46. PubMed ID: 24127013
[TBL] [Abstract][Full Text] [Related]
8. Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma.
Barbieri F; Bajetto A; Thellung S; Würth R; Florio T
Expert Opin Drug Discov; 2016 Nov; 11(11):1093-1109. PubMed ID: 27598329
[TBL] [Abstract][Full Text] [Related]
9. CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer.
Zheng N; Liu W; Chen J; Li B; Liu J; Wang J; Gao Y; Shao J; Jia L
Mol Carcinog; 2019 Jan; 58(1):144-155. PubMed ID: 30259564
[TBL] [Abstract][Full Text] [Related]
10. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells.
Luker KE; Lewin SA; Mihalko LA; Schmidt BT; Winkler JS; Coggins NL; Thomas DG; Luker GD
Oncogene; 2012 Nov; 31(45):4750-8. PubMed ID: 22266857
[TBL] [Abstract][Full Text] [Related]
11. The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma.
Li T; Li H; Wang Y; Harvard C; Tan JL; Au A; Xu Z; Jablons DM; You L
J Pathol; 2011 Mar; 223(4):519-30. PubMed ID: 21294125
[TBL] [Abstract][Full Text] [Related]
12. Overlapping and distinct role of CXCR7-SDF-1/ITAC and CXCR4-SDF-1 axes in regulating metastatic behavior of human rhabdomyosarcomas.
Grymula K; Tarnowski M; Wysoczynski M; Drukala J; Barr FG; Ratajczak J; Kucia M; Ratajczak MZ
Int J Cancer; 2010 Dec; 127(11):2554-68. PubMed ID: 20162608
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory CXCL12-CXCR4/CXCR7 axis mediates G-protein signaling pathway to influence the invasion and migration of nasopharyngeal carcinoma cells.
Qiao N; Wang L; Wang T; Li H
Tumour Biol; 2016 Jun; 37(6):8169-79. PubMed ID: 26715277
[TBL] [Abstract][Full Text] [Related]
14. Stromal cell-derived factor-1 (SDF-1) as a target in liver diseases.
Liepelt A; Tacke F
Am J Physiol Gastrointest Liver Physiol; 2016 Aug; 311(2):G203-9. PubMed ID: 27313175
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor and chemokine receptors 4 and 7 form a signaling axis to regulate CXCL12-dependent cellular motility.
Hsiao JJ; Ng BH; Smits MM; Wang J; Jasavala RJ; Martinez HD; Lee J; Alston JJ; Misonou H; Trimmer JS; Wright ME
BMC Cancer; 2015 Mar; 15():204. PubMed ID: 25884570
[TBL] [Abstract][Full Text] [Related]
16. The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer.
Shi Y; Riese DJ; Shen J
Front Pharmacol; 2020; 11():574667. PubMed ID: 33363463
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen as a modulator of CXCL12-CXCR4-CXCR7 chemokine axis: A breast cancer and glioblastoma view.
Gonçalves TL; de Araújo LP; Pereira Ferrer V
Cytokine; 2023 Oct; 170():156344. PubMed ID: 37639844
[TBL] [Abstract][Full Text] [Related]
18. CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression.
Sun X; Cheng G; Hao M; Zheng J; Zhou X; Zhang J; Taichman RS; Pienta KJ; Wang J
Cancer Metastasis Rev; 2010 Dec; 29(4):709-22. PubMed ID: 20839032
[TBL] [Abstract][Full Text] [Related]
19. CXCL12-CXCR4/CXCR7 Axis in Cancer: from Mechanisms to Clinical Applications.
Yang Y; Li J; Lei W; Wang H; Ni Y; Liu Y; Yan H; Tian Y; Wang Z; Yang Z; Yang S; Yang Y; Wang Q
Int J Biol Sci; 2023; 19(11):3341-3359. PubMed ID: 37497001
[TBL] [Abstract][Full Text] [Related]
20. CXCR7 participates in CXCL12-mediated migration and homing of leukemic and normal hematopoietic cells.
Melo RCC; Ferro KPV; Duarte ADSS; Olalla Saad ST
Stem Cell Res Ther; 2018 Feb; 9(1):34. PubMed ID: 29433559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
